• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载体蛋白受体并非高结合化合物在肝脏中快速消除的必要条件:离体灌注大鼠肝脏对普萘洛尔消除的研究。

A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: a study of propranolol elimination by the isolated perfused rat liver.

作者信息

Jones D B, Ching M S, Smallwood R A, Morgan D J

出版信息

Hepatology. 1985 Jul-Aug;5(4):590-3. doi: 10.1002/hep.1840050411.

DOI:10.1002/hep.1840050411
PMID:2991106
Abstract

The highly efficient hepatic extraction of propranolol by the isolated perfused rat liver does not diminish when albumin binding is increased from 30 to 75%. One possible explanation of this insensitivity of propranolol uptake to changes in albumin binding is the mediation of uptake of bound ligand by an albumin receptor on the hepatocyte as postulated for oleate, taurocholic acid and rose bengal. To test this hypothesis, the hepatic extraction of propranolol was studied in the isolated perfused rat liver using alpha 1-acid glycoprotein, which lacks a hepatocyte receptor, as the carrier protein in the perfusate rather than albumin. Livers were perfused with a medium containing propranolol (4 microM) and varying concentrations of alpha 1-acid glycoprotein (0 to 25 microM). Hepatic extraction of propranolol was very high (0.990 +/- 0.006; mean +/- S.D.) and did not alter significantly despite an increase in bound fraction from 0.2 to 0.8, thus closely paralleling the findings when albumin is the carrier protein. This result indicates that bound propranolol is efficiently cleared by the liver, presumably by a "free intermediate" mechanism, in the absence of a specific carrier-protein receptor on the hepatocyte. This study does not, therefore, support the albumin receptor hypothesis.

摘要

当白蛋白结合率从30%提高到75%时,离体灌注大鼠肝脏对普萘洛尔的高效肝摄取并没有降低。普萘洛尔摄取对白蛋白结合变化不敏感的一种可能解释是,如对油酸、牛磺胆酸和孟加拉玫瑰红所假设的那样,肝细胞上的白蛋白受体介导了结合配体的摄取。为了验证这一假设,在离体灌注大鼠肝脏中,使用缺乏肝细胞受体的α1 - 酸性糖蛋白作为灌注液中的载体蛋白,而非白蛋白,研究了普萘洛尔的肝摄取。用含有普萘洛尔(4μM)和不同浓度α1 - 酸性糖蛋白(0至25μM)的培养基灌注肝脏。尽管结合分数从0.2增加到0.8,但普萘洛尔的肝摄取仍然很高(0.990±0.006;平均值±标准差),且没有显著改变,因此与以白蛋白作为载体蛋白时的发现非常相似。这一结果表明,在肝细胞上不存在特异性载体蛋白受体的情况下,结合型普萘洛尔可能通过“游离中间体”机制被肝脏有效清除。因此,本研究不支持白蛋白受体假说。

相似文献

1
A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: a study of propranolol elimination by the isolated perfused rat liver.载体蛋白受体并非高结合化合物在肝脏中快速消除的必要条件:离体灌注大鼠肝脏对普萘洛尔消除的研究。
Hepatology. 1985 Jul-Aug;5(4):590-3. doi: 10.1002/hep.1840050411.
2
Propranolol metabolism by isolated hepatocytes from normal and cirrhotic rat livers: the effect of albumin.
Can J Physiol Pharmacol. 1990 Jun;68(6):657-62. doi: 10.1139/y90-098.
3
Propranolol disposition in the rat: variation in hepatic extraction with unbound drug fraction.大鼠体内普萘洛尔的处置:肝脏摄取随游离药物分数的变化
J Pharm Sci. 1992 Mar;81(3):255-8. doi: 10.1002/jps.2600810314.
4
Discrimination between the venous equilibrium and sinusoidal models of hepatic drug elimination in the isolated perfused rat liver by perturbation of propranolol protein binding.通过普萘洛尔蛋白结合的扰动来区分离体灌注大鼠肝脏中肝药物消除的静脉平衡模型和窦状隙模型。
J Pharmacol Exp Ther. 1984 May;229(2):522-6.
5
Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the isolated perfused rat liver.
Hepatology. 1984 May-Jun;4(3):461-6. doi: 10.1002/hep.1840040319.
6
Hepatic bilirubin uptake in the isolated perfused rat liver is not facilitated by albumin binding.在离体灌注大鼠肝脏中,白蛋白结合并不促进肝胆红素摄取。
J Clin Invest. 1983 Aug;72(2):718-23. doi: 10.1172/JCI111021.
7
Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug.普萘洛尔和利多卡因通过大鼠血脑屏障的转运。球蛋白结合型药物的主要作用。
J Clin Invest. 1983 Apr;71(4):900-8. doi: 10.1172/jci110844.
8
Lack of linear correlation between hepatic ligand uptake rate and unbound ligand concentration does not necessarily imply receptor-mediated uptake.肝脏配体摄取率与未结合配体浓度之间缺乏线性相关性并不一定意味着是受体介导的摄取。
J Pharmacokinet Biopharm. 1988 Aug;16(4):397-411. doi: 10.1007/BF01062553.
9
Uptake of oleate from albumin solutions by rat liver. Failure to detect catalysis of the dissociation of oleate from albumin by an albumin receptor.大鼠肝脏从白蛋白溶液中摄取油酸。未能检测到白蛋白受体催化油酸与白蛋白解离。
J Clin Invest. 1987 Apr;79(4):1070-7. doi: 10.1172/JCI112920.
10
Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.在存在尿毒症血液的情况下,灌注大鼠肝脏对异丙醇的提取减少。
J Pharmacol Exp Ther. 1985 May;233(2):277-84.

引用本文的文献

1
A Complete Extension of Classical Hepatic Clearance Models Using Fractional Distribution Parameter f in Physiologically Based Pharmacokinetics.使用生理药代动力学中的分数分布参数 f 对经典肝脏清除模型进行全面扩展。
J Pharm Sci. 2024 Jan;113(1):95-117. doi: 10.1016/j.xphs.2023.05.019. Epub 2023 Jun 4.
2
Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?是否存在更倾向于支持分配和并行管模型而不是器官消除的完全混合模型的实验灌注数据?
Drug Metab Dispos. 2020 Jul;48(7):537-543. doi: 10.1124/dmd.120.090530. Epub 2020 Apr 17.
3
Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.
使用基于生理学和经验性方法,从体外和临床前数据预测人体药物清除率。
Pharm Res. 2005 Jan;22(1):103-12. doi: 10.1007/s11095-004-9015-1.
4
Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.利用肝微粒体和分离肝细胞的体外动力学数据,比较用于预测药物清除率的肝脏模型的应用情况。
Pharm Res. 2004 May;21(5):785-92. doi: 10.1023/b:pham.0000026429.12114.7d.
5
Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination.用于精确估计肝脏消除轴向扩散模型参数的最优实验设计。
J Pharmacokinet Biopharm. 1998 Oct;26(5):595-615. doi: 10.1023/a:1023229318017.
6
The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.与白蛋白和α1-酸性糖蛋白结合对肝脏药物清除率的影响。
Pharm Weekbl Sci. 1987 Apr 24;9(2):65-74. doi: 10.1007/BF01960738.
7
Lack of linear correlation between hepatic ligand uptake rate and unbound ligand concentration does not necessarily imply receptor-mediated uptake.肝脏配体摄取率与未结合配体浓度之间缺乏线性相关性并不一定意味着是受体介导的摄取。
J Pharmacokinet Biopharm. 1988 Aug;16(4):397-411. doi: 10.1007/BF01062553.
8
Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.轴向组织扩散可以解释目前亲脂性药物肝脏消除模型之间的差异。
J Pharmacokinet Biopharm. 1992 Feb;20(1):19-61. doi: 10.1007/BF01143185.